R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 39 PLN -1.27% Market Closed
Market Cap: 901.7m PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note
Section:
 

Relative Value

The Relative Value of one RVU stock under the Base Case scenario is 42.31 PLN. Compared to the current market price of 39 PLN, Ryvu Therapeutics SA is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RVU Relative Value
Base Case
42.31 PLN
Undervaluation 8%
Relative Value
Price
R
Worst Case
Base Case
Best Case

Valuation Multiples

14.2
P/S
P/S
Price to Sales
14.2
vs History
96
vs Industry
10
Median 3Y
25
Median 5Y
50.9
Industry
4.1
Forward
5.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-12.8
Median 5Y
-12.8
Industry
32.7
Forward
-21.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
0
Median 3Y
-12.3
Median 5Y
-18.2
Industry
22.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
6
Median 3Y
-8.8
Median 5Y
-15.4
Industry
33.6
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
28
vs Industry
17
Median 3Y
5.1
Median 5Y
5.3
Industry
2.6
More Details
11.5
EV/S
EV/S
Enterprise Value to Sales
11.5
vs History
96
vs Industry
11
Median 3Y
20.6
Median 5Y
47
Industry
3.9
Forward
4.5
More Details
17.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
17.9
vs History
49
vs Industry
10
Median 3Y
26.6
Median 5Y
21.3
Industry
8.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-16.2
Industry
18.5
Forward
-19.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-10
Median 5Y
-13.2
Industry
23.7
Forward
-14.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
1
Median 3Y
-10.5
Median 5Y
-16.5
Industry
21.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
7
Median 3Y
-7.2
Median 5Y
-12.5
Industry
28.8
More Details
5.8
EV/IC
EV/IC
Enterprise Value to IC
5.8
vs History
47
vs Industry
15
Median 3Y
6.6
Median 5Y
6.8
Industry
2.4
More Details

Multiples Across Competitors

RVU Competitors Multiples
Ryvu Therapeutics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Ryvu Therapeutics SA
WSE:RVU
901.5m PLN 14.2 -8.7 -7.8 -7
US
PerkinElmer Inc
LSE:0KHE
1.2T USD 448.2 4 796.2 1 513.6 3 225.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
202B USD 4.7 32.7 21.2 30.4
US
Danaher Corp
NYSE:DHR
166.7B USD 7.8 42.5 26.7 40.1
KR
Samsung Biologics Co Ltd
KRX:207940
66.8T KRW 15.3 63.4 34.3 49.4
CH
Lonza Group AG
SIX:LONN
38.4B CHF 5.7 67 45.3 45.3
US
Agilent Technologies Inc
NYSE:A
38.7B USD 5.9 29.9 22.3 25.9
US
IQVIA Holdings Inc
NYSE:IQV
36.2B USD 2.4 25.7 14.1 21.5
US
Mettler-Toledo International Inc
NYSE:MTD
27B USD 7.1 33.7 24.1 26.9
US
West Pharmaceutical Services Inc
NYSE:WST
24.1B USD 8.3 47.9 32.3 40.6
CN
WuXi AppTec Co Ltd
SSE:603259
164.4B CNY 4.3 20.4 14.8 14.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
R
Ryvu Therapeutics SA
WSE:RVU
Average EV/EBITDA: 174.9
Negative Multiple: -7.8 		N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
1 513.6
23%
66.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
21.2
19%
1.1
US
Danaher Corp
NYSE:DHR
26.7
22%
1.2
KR
Samsung Biologics Co Ltd
KRX:207940
34.3
57%
0.6
CH
Lonza Group AG
SIX:LONN
45.3
36%
1.2
US
Agilent Technologies Inc
NYSE:A
22.3
34%
0.7
US
IQVIA Holdings Inc
NYSE:IQV
14.1
32%
0.4
US
Mettler-Toledo International Inc
NYSE:MTD
24.1
16%
1.5
US
West Pharmaceutical Services Inc
NYSE:WST
32.3
16%
2
CN
WuXi AppTec Co Ltd
SSE:603259
14.8
52%
0.3

See Also

Summary
RVU intrinsic value, competitors valuation, and company profile.
DCF Valuation
RVU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RVU stock valuation using valuation multiples.
Wall Street Estimates
RVU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RVU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.